Румъния - румънски - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

apl swift services (malta) ltd. - malta - atomoxetinum - caps. - 40mg - psihostimulante si nootrope simpatomimetice cu actiune centrala

Румъния - румънски - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

apl swift services (malta) ltd. - malta - atomoxetinum - caps. - 60mg - psihostimulante si nootrope simpatomimetice cu actiune centrala

Румъния - румънски - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

apl swift services (malta) ltd. - malta - atomoxetinum - caps. - 80mg - psihostimulante si nootrope simpatomimetice cu actiune centrala

Европейски съюз - румънски - EMA (European Medicines Agency)

esteve pharmaceuticals, s.a. - duloxetinei - anxiety disorders; depressive disorder, major; diabetic neuropathies - psychoanaleptics, - tratamentul de tulburare depresivă majoră;tratamentul durerii din neuropatia diabetică;tratamentul tulburării de anxietate generalizată;xeristar este indicat la adulți.

Румъния - румънски - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lfb - biomedicaments - franta - imunoglobulina anti-hepatitica b - pulb. + solv. sol. perf. - 50ui/ml - imunoglobuline imunoglobuline specifice

Европейски съюз - румънски - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetinei - anxiety disorders; diabetic neuropathies; depressive disorder, major - psychoanaleptics, - tratamentul tulburării depresive majore. tratamentul durerii neuropatice periferice diabetice. tratamentul tulburării de anxietate generalizată. cymbalta este indicat la adulți.

Европейски съюз - румънски - EMA (European Medicines Agency)

mylan pharmaceuticals limited - duloxetinei - neuralgia; diabetic neuropathies; depressive disorder, major; anxiety disorders - psychoanaleptics, - tratamentul de tulburare depresivă majoră;tratamentul durerii din neuropatia diabetică;tratamentul tulburării de anxietate generalizată;duloxetină mylan este indicat la adulți.

Европейски съюз - румънски - EMA (European Medicines Agency)

zentiva, k.s. - duloxetinei - neuralgia; depressive disorder, major; anxiety disorders; diabetes mellitus - alte antidepresive - tratamentul tulburării depresive, durerea neuropată diabetică, tulburarea de anxietate. duloxetine zentiva este indicat la adulți.

Румъния - румънски - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

vim spectrum s.r.l. - romania - vinpocetinum - caps. - 5mg - psihostimulante, med. utilizate in adhd si nootrope alte psihostimulante si nootrope

Европейски съюз - румънски - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinurie, paroxismal - imunosupresoare selective - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.